Available evidence suggests that melatonin-containing supplements may be associated with improved BMD in menopausal women, but the independent effect of melatonin and an optimal dose remain unclear due to heterogeneity in interventions and the prevalent use of combination therapies. For other outcomes (sleep, menopausal symptoms, mood, sexual function, BMI, and insulin), the evidence is currently inconclusive. Further large-scale RCTs are needed to confirm these findings.
Du et al. (Thu,) studied this question.